
    
      UCPVax study is a prospective multicenter phase I/II study: 54 patients with metastatic NSCLC
      will be enrolled in 5 centers in France.

      A translational research program will be performed to better define the eligibility criteria
      and predictive biomarkers needed for randomized phase II and Phase III trials.
    
  